Gilead Sciences has posted impressive performance during the fourth quarter ended December 2015. Its net profit went up by 34.3 per cent to $4,683 million from $3,487 million in the corresponding period of last year. Its net sales moved up 16.4 per cent to $8,409 million from $7,222 million. EPS went up to $3.18 from $2.18 in the last period.

The sales in US increased to $5.5 billion from $4.8 billion in the fourth quarter of last year and that in Europe increased to $1.7 billion from $1.4 billion. Sales in other international markets increased to $1.9 billion from $373 million, primarily due to sales of Sovaldi (sofosbuvir 400 mg) and Harvoni in Japan. Antiviral products sales, which include products in its HIV and liver diseases areas, were $7.9 billion as against $6.7 billion due to launch of HCV products in Japan and continued launches of HCV products across Europe. Other product sales, which include Letairis, Ranexa and AmBisome, were $523 million compared to $496 million.

For the year ended December 2015, Gilead's sales increased by 31.4 per cent to $32.2 billion from $24,5 billion in the previous year and its net profit increased strongly by 49.6 per cent to $18.1 billion from $12.1 billion. EPS worked out to $11.91 as against $7.35 in the last year. The sales increased due to sales of Harvoni which was launched in October 2014, partially offset by a decrease in sales of Sovaldi. The product sales in US were $21.2 billion compared to $18.1 billion in 2014. In Europe, its sales increased to$7.2 billion as against $5.1 billion and that in other international locations increased to $3.8 billion in 2015 compared to $1.2 billion in 2014.  

Its antiviral product sales improved by 32.5 per cent to $30.2 billion compared to $22.8 billion, mainly due to sales of Harvoni, partially offset by a decrease in sales of Sovaldi. Other product sales for 2015 were at $1.9 billion compared to $1.7 billion in the previous year. Its R&D expenditure increased to $2.8 billion from $2.6 billion due to the progression of its clinical studies. The sales of Harvoni product improved to $13.9 billion from $2.1 billion in the previous year. However, sales of Sovaldi declined sharply to $5.3 billion from $10,3 billion. The sales of Truvad improved to $3.5 billion from $3.3 billion. Atripla sales declined to $3.1 billion from $3.4 billion. The sales of complera/eviplera increased to $1.4 billion from $1.2 billion and that of Viread increased to $1.1 billion from $1.0 billion.  

The company projected product sales in the range of $30 billion to $31 billion in the year 2016 and EPS in the range of  $1.10 to $1.16. Gilead gave $73.4 million in HIV/AIDS philanthropic support in 2014.